![Julie Feder](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Feder
No más puestos en curso
Perfil
Julie B. Feder is currently Chief Financial Officer at Obsidian Therapeutics, Inc. since 2026.
Former positions include Chief Financial Officer at Aura Biosciences, Inc. from 2018 to 2024, Chief Financial Officer at Verastem, Inc. from 2017 to 2018, Chief Financial Officer at Clinton Health Access Initiative from 2011 to 2017, Vice President-Internal Audit at Genzyme Corp.
from 2008 to 2011, and Senior Manager-Audit, Consulting & Enterprise Risk at Deloitte & Touche LLP from 1991 to 2008.
Education includes undergraduate studies at Sy Syms School of Business.
Cargos activos de Julie Feder
| Empresas | Cargo | Inicio |
|---|
Antiguos cargos conocidos de Julie Feder.
| Empresas | Cargo | Fin |
|---|---|---|
| AURA BIOSCIENCES, INC. | Director Financiero/CFO | 25/10/2024 |
| VERASTEM, INC. | Director Financiero/CFO | 01/06/2018 |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Director Financiero/CFO | 01/07/2017 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Corporate Officer/Principal | 01/01/2008 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Comptroller/Controller/Auditor | - |
Formación de Julie Feder.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
96
Relaciones de 1er grado
6
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Commercial Services |
Sy Syms School of Business
 Sy Syms School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Bolsa de valores
- Insiders
- Julie Feder
